IMULAN BioTherapeutics' ImSAIDs Demonstrate Promise for Pancreatitis
prweb.com     May 16, 2008            

Canine and feline pancreatitis are disease targets for the Immune Selective Anti-Inflammatory Derivatives (ImSAIDs) from IMULAN BioTherapeutics. IMULAN BioTherapeutics, LLC (IMULAN) announced one of their lead Immune Selective Anti-Inflammatory Derivatives (ImSAIDs) has demonstrated promise for... [read full story]                

Add a comment to the article
Type the code shown

View all news articles about:

- Related Topics

View other selected articles:

                   

International Struggle to Develop HIV/AIDS Vaccine Continues

newsblaze.com     16 hrs ago   43 related          

By Cheryl Pellerin The 20-year effort to develop a vaccine that protects against the AIDS-causing human immunodeficiency virus (HIV) meets more challenges as clinical trials are discontinued and the National Institute of...                

comments

                   

Hyperactive immune resistance brings blindness in old age

brightsurf.com     19 hrs ago   3 related          

Recent discoveries regarding the origins of senile blindness Age-dependent macular degeneration (AMD) is the commonest cause of blindness in the western industrialised nations. Hereditary changes in the regulation of the immune...                

comments

People With GERD More Likely to Develop Asthma (HealthDay)

yahoo.com     21 hrs ago   5 related          

FRIDAY, July 25 (HealthDay News) -- The first evidence linking gastroesophageal reflux disease (GERD) and asthma has been discovered by Duke University Medical Center researchers. An association between the two conditions was...                

comments

Induction of tolerance to cardiac allografts using donor splenocytes engineered to display on...

biowizard.com     Jul 24, 2008          

Department of Microbiology and Immunology, Institute for Cellular Therapeutics, University of Louisville, Louisville, KY 40202, USA. e0yolc01@gwise.louisville.edu The critical role played by Fas ligand (FasL) in immune...                

comments